Phase 2/3Completed
Aspirin in Colorectal Cancer Liver Metastases (ASAC)
Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer
- Sponsor
- Oslo University Hospital (Academic or other)
- Enrolment
- 466 enrolled
- Conditions
- Colorectal Cancer Liver Metastases; Colorectal Cancer; Liver Metastases
- Interventions
- Acetylsalicylic acid; Placebo Oral Tablet
- Ages
- adults, older adults
- Registry
- NCT03326791
Full record on ClinicalTrials.gov
From the registry
The ASAC trial is a Scandinavian, multi-center, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose acetylsalicylic acid (ASA) can improve disease free survival in patients treated with resection for colorectal cancer liver metastases (CRCLM). Several studies have shown beneficial effect of ASA on primary prevention of CRC and the investigators group and others have shown a potential association of ASA also taken after the diagnosis on CRC survival in registry-based studies (secondary prevention). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo for a period of 3 years or till disease recurrence. The patients will be treated and followed up according to standard of care and the National Guidelines. The ASAC trial will be the first clinical interventional trial to assess the beneficial role of ASA in recurrence of CRC liver metastases and survival. ASA is an inexpensive, well tolerated, and easily accessible drug that will be highly potential as adjuvant drug in secondary…
Primary outcomes
- Disease Free Survival (DFS) after three years treatment
History
Last registry update
Study completion
Primary completion
Started
Registered